Literature DB >> 29171332

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.

Abdul Rafeh Naqash1, Li V Yang1, Edward J Sanderlin1, Druid C Atwell1, Paul R Walker2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29171332     DOI： 10.1080/0284186X.2017.1406668

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  21 in total

Review 1.  The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.

Authors:  Arabella Young; Zoe Quandt; Jeffrey A Bluestone
Journal:  Cancer Immunol Res       Date:  2018-12       Impact factor: 11.151

2.  Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model.

Authors:  Silvia Ippolito; Giulia Di Dalmazi; Fabiana Pani; Elena Sabini; Patrizio Caturegli
Journal:  Thyroid       Date:  2021-12       Impact factor: 6.568

Review 3.  Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management.

Authors:  Virginia Robles-Alonso; Fernando Martínez-Valle; Natalia Borruel
Journal:  Front Med (Lausanne)       Date:  2022-06-30

4.  Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer.

Authors:  Yingying Yu; Siyu Wang; Nan Su; Shida Pan; Bo Tu; Jinfang Zhao; Yingjuan Shen; Qin Qiu; Xiaomeng Liu; Junqing Luan; Fu-Sheng Wang; Fanping Meng; Ming Shi
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 5.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

6.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Authors:  Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2019-06-19       Impact factor: 50.717

7.  Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.

Authors:  Abdul Rafeh Naqash; Ebenezer Appah; Li V Yang; Mahvish Muzaffar; Mona A Marie; Justin D Mccallen; Shravanti Macherla; Darla Liles; Paul R Walker
Journal:  J Immunother Cancer       Date:  2019-07-05       Impact factor: 13.751

Review 8.  The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.

Authors:  Xiaoyang Zhai; Jian Zhang; Yaru Tian; Ji Li; Wang Jing; Hongbo Guo; Hui Zhu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

Review 9.  The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review.

Authors:  Alistair R Miller; Renee Manser
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 10.  Management of immune checkpoint inhibitor-related adverse events: A review of case reports.

Authors:  Xiaoyan Si; Peng Song; Jun Ni; Mingyi Di; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xu Yang; Mengzhao Wang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-01-22       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.